CN103989589B - Beans extract containing coumestrol or comprising coumestrol, cosmetic composition for skin nursing - Google Patents
Beans extract containing coumestrol or comprising coumestrol, cosmetic composition for skin nursing Download PDFInfo
- Publication number
- CN103989589B CN103989589B CN201410243191.4A CN201410243191A CN103989589B CN 103989589 B CN103989589 B CN 103989589B CN 201410243191 A CN201410243191 A CN 201410243191A CN 103989589 B CN103989589 B CN 103989589B
- Authority
- CN
- China
- Prior art keywords
- coumestrol
- skin
- composition
- cell
- beans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 title claims abstract description 173
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 244000046052 Phaseolus vulgaris Species 0.000 title claims abstract description 42
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 230000000474 nursing effect Effects 0.000 title abstract description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 9
- 229960002986 dinoprostone Drugs 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 229940021414 skin shield Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 41
- 238000000034 method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 239000000470 constituent Substances 0.000 description 21
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 11
- 210000004927 skin cell Anatomy 0.000 description 11
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 10
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- 241000522215 Dipteryx odorata Species 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 230000009759 skin aging Effects 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 206010027654 Allergic conditions Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 235000010582 Pisum sativum Nutrition 0.000 description 3
- 240000004713 Pisum sativum Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000006677 Vicia faba Species 0.000 description 2
- 235000010749 Vicia faba Nutrition 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical class OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000003483 aging Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000922 anti-bactericidal effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- JBIZUYWOIKFETJ-UHFFFAOYSA-N coumestan Chemical compound O1C2=CC=CC=C2C2=C1C(C=CC=C1)=C1OC2=O JBIZUYWOIKFETJ-UHFFFAOYSA-N 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
The present invention relates to a kind of cosmetic composition for skin nursing, the composition contains coumestrol, or contains the beans extract comprising coumestrol.
Description
Technical field
The present invention relates to a kind of skin care compositions and methods, which contains coumestrol
（Coumestrol）, or contain the beans extract comprising coumestrol.
Background technology
With the increase of average human life, how to keep young more important than how to survive for a long time for a long time.With
The age of people increases, and aging is an inevitable process.Especially since modern society environment pollution and pressure are increasingly
Serious and UV light exposure increase, aging are early before starting to compare.
All gradual agings of human organ, and skin aging is affected by especially greatly.Most early stages
Skin aging all starts from dry skin.When skin becomes dry, it can follow the string, and can become easy generation wrinkle.Skin
After skin aging, the regeneration of skin takes a long time, since keratinized skin can become coarse, because of the reduction production of collage synthesis
Raw wrinkle.Since the reduction of ultraviolet protection generates the pigmentations such as freckle, spot living, because of the decrease of skin sparing, skin becomes
It obtains and is easily attacked by drug or external environment stimulation.
Invention content
Technical problem
The present invention is intended to provide a kind of coumestrol containing as active constituent, or the beans extract comprising coumestrol
Skin care compositions and methods.
The present invention is also directed to a kind of skin care compositions and methods as cosmetic composition, contain as activity at
The coumestrol divided or the beans extract comprising coumestrol.
Technical solution
On the one hand, the present invention provides a kind of coumestrol containing as active constituent or the extraction of the beans comprising coumestrol
The skin care compositions and methods of object.
Technique effect
The skin care compositions and methods of the present invention, which provide, to be improved skin elasticity, improves wrinkle of skin, skin whitening, moistens
Skin anti-inflammatory, antibacterial, prevents skin aging, is anti-oxidant, improves acne, improve atopic dermatitis, alleviate skin irritatin, maintain
Skin-balance and the effect for alleviating or improving skin allergy, are widely used in such as cosmetics or field of food.
Specific implementation mode
Term " extract " used herein refers to the substance extracted from natural materials, no matter extracting method or at
Point.Using the meaning of term broad sense, including, such as water soluble ingredient or the organic solvent that is extracted from natural materials using solvent
Or the special component in natural materials, the oil such as wherein extracted.
Term " skin " used herein refers to the tissue for being covered in animal bodies surface, using extensive connotation, includes not only
The tissue of covering face or body, further includes scalp and hair.
Term " skin nursing " used herein includes any treatment or the shield for improving skin appearance and skin health
Reason.
Next it will be described in the present invention.
On the one hand, the present invention provides a kind of coumestrol containing as active constituent or the beans comprising coumestrol carry
Take the skin care compositions and methods of object.
Coumestrol（CMS；3,9- dihydroxy -6H- benzofurans (3,2-c) (1) chromene -6- ketone）With chemical formula
1 structure.
Chemical formula 1
Coumestrol is a kind of phytoestrogen, can generally be found in the seed of pulse family or feverfew, root or leaf.
It can be classified as coumestan quasi-isoflavones, it is known that it has the function of estrogen.
The present invention an exemplary embodiments in, the skin care compositions and methods include coumestrol, containing tonka-bean it is female
The natural materials of phenol or its extract.In another exemplary embodiments of the present invention, the natural materials containing coumestrol can
To be selected from soybean, pea, mung bean and from the bean sprouts that these beans are sent out, red clover（Clover）, in brussels sprout or the like
One or more beans.In another exemplary embodiments of the present invention, the natural materials containing coumestrol can be beans.
In the exemplary embodiments of the present invention, the beans can be any legume containing coumestrol, and
It is not particularly limited.For example, beans used in the present invention can be for thick broad-bean sauce, bean curd, bean sprouts, beans rice mixture or not at
The beans of ripe beans.Kind for thick broad-bean sauce or the beans of bean curd include great Feng, lake sauce, champion, rheum officinale, small courage, crane, big member,
Genuine piece albumen, soya-bean oil, new eight is reached, light, Wan Li, longevity, unlimited, white clouds, bird ovum, gold and is come into leaves very much.Beans for bean sprouts
Kind includes mythology, roundlet, Anping, southwest, colorful, small green, lakelet, dredges bright, polynary, high yield bean sprouts, the bean sprouts Yi Shan, small white peas or beans
Bud, light peace, short leaf and the milky way.The kind of beans for beans rice mixture includes green magnetic, black green, brown taste, fresh black, black soya bean and a product
Black soya bean.In addition, how towering the kind of the beans for immature beans is tight underdone including, fresh green, new second, black second, sunset cool underdone beans, China
Beans and big second.In another embodiment of the present invention, the beans can be that can germinate and have to the infringement of disease and pest
The beans of resistance.For example, the kind of the beans includes such as mythology, roundlet, Anping, southwest, colorful, small green, lakelet, thin bright, more
Member, high yield bean sprouts, the bean sprouts Yi Shan, small white peas or beans bud, light peace, short leaf and the milky way.
In the exemplary embodiments of the present invention, natural materials and its extract can contain a large amount of coumestrol.Tool
Body, coumestrol can account for the natural materials or the 0.01-50wt% of its extract total weight, more particularly 0.1-
30wt%。
In the exemplary embodiments of the present invention, under normal temperature or hot conditions, contained with water or ethyl alcohol extraction
The natural materials of coumestrol, the extract that concentration generates completely is water-dispersible again, with isometric selected from hexane, dichloro
One or more solvents in methane, chloroform, ethyl acetate, butanol, ethyl alcohol, first alcohol and water are fractionated to be contained
There is the extract of the natural materials of the coumestrol.But extracting method is not limited to that, can be used any other
Extracting method.
The present invention an exemplary embodiments in, the skin care compositions and methods can be for improve skin elasticity or
The skin care compositions and methods of wrinkle.Containing the coumestrol as active constituent in composition, can inhibit as clostridiopetidase A
Fibroblast collagenase（MMP-1）Expression, promote I type pN- collagens synthesis, inhibit Skin Cell saccharification, promote
Into the generation of ATP in cell.The composition containing the coumestrol as active constituent, passes through these behaviors, it is possible to provide
Improve the better effect of skin elasticity and wrinkle.Specifically, the composition has to improving UV-induced wrinkle of skin
There is superior effect.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be the combination for skin whitening
Object.Coumestrol containing in the composition, as active constituent, can obviously remove due to skin aging or ultraviolet irradiation
The active oxygen of generation inhibits the generation of melanin, reduces the saccharification of Skin Cell.By these activity, containing as activity at
The composition of the coumestrol divided can provide superior skin-whitening effect.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be the combination for skin care
Object.The coumestrol as active constituent contained in the composition reduces the consumption of moisture in skin, by promoting cell
The synthesis of middle ATP has splendid ability to the regeneration of skin.Pass through these activities, the perfume (or spice) containing as active constituent
The composition coumestrol of the female phenol of beans can provide splendid skin moisturizing effect.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be anti-inflammatory and bactericidal composition.
The coumestrol as active constituent contained in the composition inhibits prostaglandin E2（PGE2）Generation, promote cell
The synthesis of middle ATP, by inhibiting liopopolysaccharides（LPS）The biosynthesis of caused cyclooxygenase-2 (COX-2), to inhibit inflammation
Reaction, protects the skin from the influence of microorganism or bacterium.By these activities, contain the coumestrol as active constituent
The composition can provide splendid anti-inflammatory and antibacterial action.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be for preventing skin aging
Composition is used for oxidation resistant composition.With the increase at age, collagen, elastin laminin, hyaluronic acid and glycoprotein
Content and arrangement mode can change or reduce.Meanwhile skin can be by free radical or the oxidative stress of active oxygen.It is described
The coumestrol as active constituent contained in composition to Scavenger of ROS, improve skin elasticity and wrinkle of skin have it is splendid
Effect, and have better skin-whitening and skin moisturizing effect, and by promotion Skin Cell energetic supersession, pole is provided
The good effect for inhibiting skin aging or oxidation.By these activities, contain described group of the coumestrol as active constituent
The excellent effect for preventing skin aging or oxidation can be provided by closing object.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be the combination for improving acne
Object.The coumestrol as active constituent contained in the composition inhibits the generation of PGE2, controls sebum and passes through inhibition
The biosynthesis of COX-2 caused by LPS, to inhibit inflammatory reaction, to provide the effect for improving acne and skin problem.Pass through
These activities, the composition containing the coumestrol as active constituent can provide the effect for improving acne.
In the exemplary embodiments of the present invention, the skin care compositions and methods can be the group for improving atopic dermatitis
Close object.Because there is the coumestrol as active constituent contained in composition splendid skin moisturizing, anti-inflammatory and antibacterial to make
With and fabulous Skin Cell power of regeneration, so it can improve atopic dermatitis.
In the exemplary embodiments of the present invention, the skin care compositions and methods can mitigate skin allergy or maintenance
The composition of skin-balance.The coumestrol as active constituent contained in the composition inhibits the generation of PGE2, passes through
The biosynthesis for inhibiting COX-2 caused by LPS prevents scytitis and extraneous nuisance to inhibit inflammatory reaction to provide
The effect damaged caused by matter.By these activities, the composition containing the coumestrol as active constituent can lead to
It crosses and mitigates the skin irritatin caused by the harmful external factor such as chemicals, atmosphere pollution, ultraviolet light to protect skin and dimension
Hold the effect of skin-balance.
In the exemplary embodiments of the present invention, the skin care compositions and methods can mitigate or prevent skin allergy
Composition.The coumestrol as active constituent contained in the composition has better skin moisturizing, anti-inflammatory and resists
Bacterium acts on and splendid Skin Cell palingenesis.Therefore, contain the composition of the coumestrol as active constituent
Can have the function of alleviating or preventing skin allergy.
According to one embodiment of present invention, the composition contains the 0.001- for accounting for the composition total weight
30wt%, preferably 0.01-10wt%, the coumestrol of more preferable 0.1-5wt% or the beans extract containing coumestrol.Work as tonka-bean
Female phenol or beans extract containing coumestrol within the above range when, can fully realize the desired effect of the present invention, and stablize
Property and safety are satisfactory, and can realize advantageous cost-effectiveness.
According to one embodiment of present invention, the skin care compositions and methods can be cosmetic composition.The makeup
The medium or alkali that product composition allows containing beauty product or skin.It can be made into any topical application form, such as molten
Liquid, gel, powder, cream, without aqueous slurry, emulsion oil-in-water, water-in-oil emulsion, multiple emulsion（multiemulsion）, it is outstanding
Supernatant liquid, microemulsion, microcapsules, particle, ion（Liposome）Or it the vesicular dispersions of nonionic, foam or is promoted containing pressurization
The aerosol composition of agent.These compositions can be prepared by the method for generally use in the prior art.
The cosmetic composition can also include lipid material, organic solvent, solubilizer, thickener, gelling agent, softness
Agent, antioxidant, suspending agent, stabilizer, foaming agent, aromatic, surfactant, water, ionic emulsifying agent or non-ionic emulsifier
Agent, filler, sequestering agent, chelating agent, preservative, vitamin, blocking agent, moisturizer, essential oil, dyestuff, pigment, hydrophily
Or hydrophobic active agent, lipid vesicle or cosmetics or the usually used other adjuvants of dermatology.The addition of these adjuvants
Amount is the usual amounts of cosmetics or dermatological field.
The cosmetic composition is not specifically limited to the dosage form referred to, can select suitable dosage form according to purposes.For example,
The cosmetic composition can be prepared as selected from toner, lotion, essence, creams, ointment, gelling agent, facial mask, patch, spray
Mist agent, lotion bottom powder, hides flaw stick, hand or foot lotion, hand or foot creams, hand or foot oil, hand or foot at foundation cream
One or more doses in portion's essence, hand or foot detergent, soap, cleansing cream, cleaning lotion, cleaning foam and clean water
Type, it is not limited to this.
According to one embodiment of present invention, the skin care compositions and methods can be food compositions.The food group
Closing object can be made into such as tablet, granule, potus, caramel, it is not limited to this.In addition to active constituent, the food
Each dosage form of composition may also include ingredient commonly used in the art.According to usage, those skilled in the art can have no
The ingredient is difficulty selected, and the ingredient can provide synergistic effect.
Those skilled in the art can determine that the dosage of the active constituent.For example, the dosage can be 0.1-5000
Mg/kg/ days, preferably 50-500mg/kg/ days, it is not limited to this, and age that the dosage can be because for the treatment of object, physiology item
The difference of the factors such as part, complication and change.
The feature of the present invention and effect will be described in detail by testing example.But following testing example
Illustrative purposes are used only as, are not intended to limit the scope of the invention.
The active oxygen radical that [testing example 1] induces UVB-（ROS）Scavenging effect evaluation
With 2 ', 7 '-dichlorofluorescin diethylesters（DCFH-DA, Molecular Probes companies, Oregon are beautiful
State）To evaluate the active oxygen radical that coumestrol induces UVB-（ROS）Scavenging effect.DCFH-DA is a kind of fat-soluble
Substance, it is known that the detection agent as ROS in cell.It can be easy to be absorbed by cell, and in cell under the action of esterase, hair
The hydrolysis of raw acetate group, is converted to 2 ', 7 '-dichlorofluorescins.Due to 2 ', 7 '-dichlorofluorescins and cell
2 ', the 7 '-dichlorofluoresceins for sending out fluorescence are converted to after interior oxidant reaction（DCF）, so measurement DCFH-DA can be passed through
The fluorescence intensity of the cell of processing evaluates the quantity of intracellular ROS.
By angle albuminous cell（It is obtained from doctor Fusenig of German Cancer Research Centre）It is inoculated into 96 hole black plates
（Greiner BioOne companies, North Carolina State, the U.S.）Upper to be used for fluorometric investigation, density is per hole 1x104A cell, training
It supports 24 hours.Then, in the culture medium of fresh no FBS, to be diluted to ultimate density be 0.01,0.1 or 1 μM of tonka-bean
Female phenol handles the cell.After test substances are added, culture cell 24 hours.With HEPES buffer salt solutions（HCSS）It rinses
After removing remaining culture medium, DCFH-DA and HCSS mixed liquors are added（DCFH-DA：20 μM, HCSS：100μL）.It will be described
Cell is in 37 DEG C and 5%CO2Under the conditions of, culture rinses cell after twenty minutes, with HCSS.Then, the HCSS of 100 μ L is added, uses
30mJ/cm2UVB irradiated cells, with induce generate ROS.Then, the coumestrol of same concentrations is diluted in HCSS,
In 37 DEG C and 5%CO2Under the conditions of, culture cell 3 hours.Coumestrol Wallac VICTOR2 fluorimeters（Wallac, Tu Er
Library, Finland）Under conditions of excitation wavelength 485nm and launch wavelength 530nm, the fluorescence intensity of DCF is measured.Pass through the glimmering of measurement
Luminous intensity calculates the ROS scavenging effects relative to control group（%）.It the results are shown in Table 1.
[table 1]
As can be seen from Table 1, coumestrol has the function of removing the ROS of UVB- inductions, acts on coumestrol
The increase of concentration and increase.Therefore, the composition containing coumestrol, which can provide, inhibits the skin oxidative caused by UV, inhibits light
The effect of aging and skin whitening.
The evaluation of [testing example 2] to the inhibiting effect of the UV- MMP-1 expression induced
Use human body fibroblast（CAS-C-004-5C, Invitrogen, California, the U.S.）To evaluate tonka-bean
Inhibiting effect of the female phenol to the UV- MMP-1 expression induced.24 orifice plates are seeded cells into, density is per hole 1x104A cell,
It is cultivated in the culture medium containing 10%FBS about 24 hours, until about 80% is paved with.With the culture medium of no FBS instead before
After culture medium, culture cell 24 hours.After being rinsed 1 time with PBS, 100 μ L PBS are added, with 15 mJ/cm2UVB irradiation it is thin
Born of the same parents.It is in the culture medium of fresh no FBS, to be diluted to ultimate density be 0.01,0.1 or 1 μM of tonka-bean after removing PBS
Female phenol handles cell.After being handled 48 hours with test substances, the expression of MMP-1 is evaluated.Supernatant is collected from cell culture
Afterwards, enzyme linked immunosorbent assay (ELISA) is used（ELISA）Kit（RPN 2610, Biotrak Amersham Pharmacia
Biotech, Britain）To evaluate the expression of MMP-1.The quantity of MMP-1 is measured by total protein concentration.Calculate the activity of MMP-1
（%）, the results are shown in Table 2.
[table 2]
As can be seen from Table 2, coumestrol has the active abilities of MMP-1 for inhibiting UV- inductions, and the ability is with perfume (or spice)
The increase of the female phenol concentration of beans and enhance.Therefore, the composition containing coumestrol can be come by the damage of inhibition collagen
Improve skin elasticity and wrinkle.
The effect assessment of [testing example 3] to I type pN- collagen synthesis
Use human body fibroblast（CAS-C-004-5C, Invitrogen, California, the U.S.）To evaluate tonka-bean
Synthesis of the female phenol to I type pN- collagens.24 orifice plates are seeded cells into, density is per hole 1x104A cell, containing
It is cultivated in the culture medium for having 10%FBS about 24 hours, until about 80% is paved with.It is in the culture medium of fresh no FBS, dilute
It releases the coumestrol for being 0.01,0.1 or 1 μM to ultimate density and handles the cell.After being handled 48 hours with test substances,
Supernatant is collected from cell culture, with IC procollagen types-peptide（PIP）EIA kits（MK 101, Takara
Shuzo, capital of a country, Japan）To measure the synthesis quantity of I type pN- collagens.I type pN- collagen eggs are measured by total protein concentration
White quantity.The synthesis quantity for calculating I type pN- collagens, the results are shown in Table 3.
[table 3]
As can be seen from Table 3, coumestrol promotes the synthesis of I type pN- collagens.Therefore, containing coumestrol
Composition can improve skin elasticity and wrinkle.
The evaluation for the inhibiting effect that [testing example 4] is saccharified to Skin Cell
Use human body fibroblast（CAS-C-004-5C, Invitrogen, California, the U.S.）To evaluate tonka-bean
The inhibiting effect that female phenol is saccharified to Skin Cell.6 orifice plates are seeded cells into, density is per hole 5x104A cell, containing
It is cultivated in the culture medium of 10%FBS about 24 hours, until about 80% is paved with.After being rinsed 1 time with PBS, 100 μ L PBS are added, use
50mJ/cm2UVB irradiated cells.It is in the culture medium of fresh no FBS, be diluted to ultimate density and be after removing PBS
2.5 μM of coumestrol handles the cell.After being handled 24 hours with test substances, Oxiselect is usedTMAdvanced glycation final product
（AGE）ELISA kit evaluates the saccharification of Skin Cell.The concentration of glycation end product is measured, as shown in table 4.
[table 4]
As can be seen from Table 4, coumestrol inhibits the saccharification of Skin Cell.Therefore, the composition containing coumestrol
Skin elasticity can be improved and the effect of skin whitening is provided.
The evaluation of [testing example 5] ATP nucleus formations
To human body fibroblast（CAS-C-004-5C, Invitrogen, the state of Colorado, the U.S.）It is real to carry out test
After the processing for applying example 4, with ATP assay kits（Invitrogen, A22066）Evaluate the generation of ATP in cell.It measures
The concentration of ATP is as shown in table 5.
[table 5]
As can be seen from Table 5, coumestrol promotes the generation of ATP in cell.Therefore, the composition containing coumestrol
It can promote skin regeneration, by promoting the energetic supersession of Skin Cell to improve skin elasticity and activating skin cells.
The evaluation of [testing example 6] to the inhibiting effect of melanin production
The mouse melanocytes of C57BL/6 mouse will be derived from（Mel-Ab cells）, in 37 DEG C and 5% CO2In, contain 10%
FBS, 100nM 2- oxygen-tetradecanoylphorbol-13-acetate（2-O-tetradecanoylphorbol-13-acetate）
The Eagles culture mediums improved with the Dulbecco of 1 nM cholera toxins（DMEM）Middle culture.Divided with 0.25% trypsase-EDTA
It from the Mel-Ab cells after culture, and is cultivated on 24- orifice plates, per hole 105A cell.Since second day, it is added for three days on end
0.01,0.1 or 1 μM of coumestrol.Then, it after removing culture medium, is rinsed with PBS, cell is suspended in the sodium hydroxide of 1N
In, measure the absorbance at 400nm.Use 10 μM of hydroquinone as positive controls, it is known that it has remarkable melanin
Generation inhibiting effect.Melanin production inhibiting effect is calculated according to the absorbance of measurement（%）, the results are shown in Table 6.
[table 6]
As can be seen from Table 6, coumestrol has splendid melanin production inhibiting effect.Therefore, containing coumestrol
Composition can have remarkable skin-whitening effect.
[testing example 7] is to prostaglandin E2（PGE2）The evaluation of the inhibiting effect of generation
The inhibiting effect that test coumestrol generates prostaglandin E2 as follows.By human body fibroblast
（CAS-C-004-5C, Invitrogen, California, the U.S.）In CO2It is cultivated 24 hours in incubator.With fresh nothing
After the culture medium of FBS replaces culture medium, cultivate 2 hours, be then used in it is in the culture medium of fresh no FBS, be diluted to most
Final concentration of 0.01,0.1 or 1 μM of coumestrol handles cell.Then by cell and 37 DEG C and 5%（Volume ratio）CO2Training
It supports and is cultivated 2 hours in case.Then, cell is handled 5 minutes with stimulation with 50 μM of calcium ion carrier A 23187 and arachidonic acid
Prostaglandin E2, cell cracking measure the absorbance at 450nm to quantify prostaglandin E2 with ELISA readers, the results are shown in Table
7.It calculates relative to the inhibiting effect without coumestrol processing group（%）.It measures 5 times, results are averaged.
[table 7]
As shown in Table 7, coumestrol can inhibit the generation of prostaglandin E2.Therefore, the composition tool containing coumestrol
There is antiinflammation, sebum secretion can be prevented, alleviate skin problem, improve acne and skin allergy.
[testing example 8] is to liopopolysaccharides（LPS）The cyclooxygenase-2 of induction（COX-2）The inhibition of biosynthesis is made
Evaluation
Use human body fibroblast（CAS-C-004-5C, Invitrogen, California, the U.S.）It is female to evaluate tonka-bean
Inhibiting effect of the phenol to COX-2 biosynthesis.6 orifice plates are seeded cells into, density is per hole 5x104A cell is containing 10%
It is cultivated in the culture medium of FBS about 24 hours, until about 80% is paved with（80% confluency）.Used in the culture of fresh no FBS
It is in base, be diluted to ultimate density be 0.01,0.1 or 1 μM coumestrol handle cell, then at 37 DEG C and 5%（Volume ratio）
CO2It is cultivated 24 hours in incubator.Cell is harvested, immunoblotting is used in combination to quantify the COX-2 of generation.It calculates opposite
In the COX-2 expressions of control group（%）, the results are shown in Table 8.
[table 8]
As shown in Table 8, coumestrol inhibits the biosynthesis of the COX-2 of LPS inductions.Therefore, containing coumestrol
Composition can provide antiinflammation, improve acne and skin allergy.
The evaluation of [testing example 9] to the improvement result of atopic dermatitis
It will be diagnosed as with allergic conditions（It itches, blister or serious drying）Or show atopic symptom
- 50 years old 10 years old 30 people are divided into 2 groups, give the ointment containing 0.1% coumestrol or the ointment without coumestrol respectively（It is right
According to group）.It is required that they apply above-mentioned ointment continuous 12 weeks at the position of its allergic conditions, twice daily.After 12 weeks, pass through tune
Look into the improvement of questionnaire test allergic conditions.The classical symptom for checking atopic dermatitis includes " itching ", " drying ", " cutin
Change ", " dandruff ", " erythema ", " swelling ", the improvement of " fissure of skin ", " secretion and eczema ".Subject is allowed to be the improvement of symptom
Situation is given a mark, and is averaged to evaluate the improvement of atopic dermatitis, be the results are shown in Table 9.
[table 9]
As can be seen from Table 9, coumestrol and the composition containing coumestrol have the work for improving atopic dermatitis
With.
The evaluation of [testing example 10] to the improvement result of skin moisture-keeping
In order to evaluate the improvement of skin moisture-keeping ability, in constant temperature, constant humidity（24 DEG C, relative humidity 40%）Under the conditions of, use skin
Moisture tester measures the percutaneous moisture loss of subject in testing example 9, and results are averaged, is shown in Table 10.
[table 10]
As can be seen from Table 10, coumestrol can inhibit the loss of percutaneous moisture, and with the extension of time, inhibiting effect
It can increase.Therefore, the composition containing coumestrol can provide the effect of skin moisture-keeping.
The Formulation Example of the present composition is described below, but the scope of the present invention is not limited merely to following reality
Apply example.
[Formulation Example 1] skin softening lotion
According to the method for generally use, skin softening lotion is prepared with the ingredient described in table 11.
[table 11]
[Formulation Example 2] nutrient lotion
According to the method for generally use, nutrient lotion is prepared with the ingredient described in table 12.
[table 12]
[Formulation Example 3] moisturizer
According to the method for generally use, moisturizer is prepared with the ingredient described in table 13.
[table 13]
[Formulation Example 4] tablet
By coumestrol（80mg）, vitamin E（9mg）, vitamin C（9mg）, galactooligosaccharide（200mg）, lactose
（60mg）And maltose（140mg）Mixing is granulated with vulcanization drying bed.Sugar ester is added（6mg）Afterwards, according to the side of generally use
Method, by the composition of gained（500mg）Prepare piece agent.
[Formulation Example 5] potus
By coumestrol（80mg）, vitamin E（9mg）, vitamin C（9mg）, glucose（10g）, citric acid（0.6g）With
Oligosaccharides syrup（25g）Mixing.Pure water is added（300mL）Afterwards, mixture obtained by 200mL is filled into bottle.Then, 130
Potus is just made in 4-5 seconds in DEG C disinfection.
It will be understood by those skilled in the art in the scope of the present invention, can carry out various changes to the present invention or repair
Change.
Claims (3)
1. coumestrol or the beans extract comprising coumestrol are preparing the skin shield for alleviating or improving skin allergy
Application in physics and chemistry cosmetic compositions,
Wherein, the skin allergy is caused by the increase of COX-2 or prostaglandin E2 in the fibroblast of skin.
2. application according to claim 1, which is characterized in that the composition, which contains, accounts for the composition total weight
The coumestrol of 0.001-30wt% or beans extract containing coumestrol.
3. application according to claim 1 or 2, which is characterized in that the composition is cosmetic composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0029164 | 2010-03-31 | ||
| KR20100029164 | 2010-03-31 | ||
| CN2011800263374A CN102905685A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or bean extract containing coumestrol for skin care |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800263374A Division CN102905685A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or bean extract containing coumestrol for skin care |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103989589A CN103989589A (en) | 2014-08-20 |
| CN103989589B true CN103989589B (en) | 2018-08-21 |
Family
ID=44720419
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510909598.0A Pending CN105362151A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care |
| CN2011800263374A Pending CN102905685A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or bean extract containing coumestrol for skin care |
| CN201410243191.4A Active CN103989589B (en) | 2010-03-31 | 2011-03-31 | Beans extract containing coumestrol or comprising coumestrol, cosmetic composition for skin nursing |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510909598.0A Pending CN105362151A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care |
| CN2011800263374A Pending CN102905685A (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or bean extract containing coumestrol for skin care |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9265707B2 (en) |
| KR (3) | KR20110110052A (en) |
| CN (3) | CN105362151A (en) |
| WO (1) | WO2011122869A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101854158B1 (en) * | 2011-10-24 | 2018-06-14 | (주)아모레퍼시픽 | Skin External Composition Containing Extracts of Soybean Flower |
| KR102063686B1 (en) * | 2012-01-02 | 2020-02-11 | (주)아모레퍼시픽 | Skin external composition containing extract of soybean root |
| KR102033448B1 (en) * | 2012-07-31 | 2019-10-17 | (주)아모레퍼시픽 | Composition for antiinflammation containing extract of soybean root |
| KR102014960B1 (en) * | 2012-07-31 | 2019-08-28 | (주)아모레퍼시픽 | Composition for anti oxidation containing extract of soybean root |
| KR101957845B1 (en) * | 2012-07-31 | 2019-03-14 | (주)아모레퍼시픽 | Composition for improving condition of hair and scalp containing extract of soybean root |
| KR102014962B1 (en) * | 2012-08-02 | 2019-08-28 | (주)아모레퍼시픽 | Composition for antiinflammation containing extract of soybean pod |
| KR101985356B1 (en) * | 2012-08-03 | 2019-06-04 | (주)아모레퍼시픽 | Composition for skin external application containing fermented soybean extract |
| KR101989067B1 (en) * | 2013-02-28 | 2019-06-14 | (주)아모레퍼시픽 | Composition Containing Coumestrin |
| KR102200014B1 (en) * | 2013-05-06 | 2021-01-08 | (주)아모레퍼시픽 | Composition for preventing and treating climacteric symptoms comprising extract of bean containing coumestrol |
| BR112016002732A2 (en) * | 2013-08-09 | 2017-08-01 | Unilever Nv | topical or oral or parenteral composition to improve blood micro / macrocirculation and use thereof |
| FR3015526B1 (en) * | 2013-12-20 | 2017-02-17 | Oreal | NPY1R BIOMARKER OF LENTIGO ACTINIQUE |
| US9730972B1 (en) * | 2016-06-13 | 2017-08-15 | Ashley Diana Black International Holdings, Llc | Skin tightening lotion |
| US20190134129A1 (en) | 2017-11-06 | 2019-05-09 | Sinotai Oncology Associate., Ltd. | Method for alleviating ultraviolet damage with ethyl acetate-extracted product of sedum formosanum |
| KR102226151B1 (en) * | 2017-11-20 | 2021-03-11 | (주)아모레퍼시픽 | Method for producing coumestrol using leguminous plants |
| KR20200040583A (en) * | 2018-10-10 | 2020-04-20 | (주)아모레퍼시픽 | Composition for cortisone reductase inhibition |
| KR102249711B1 (en) * | 2018-10-23 | 2021-05-10 | (주)아모레퍼시픽 | Composition for enhancing skin elasticity or improving skin wrinkels comprising enzyme treated extract of leguminous plants cultured root |
| KR101997033B1 (en) * | 2018-11-19 | 2019-07-08 | (주)아모레퍼시픽 | Composition for antiinflammation containing extract of soybean root |
| CN116270281A (en) * | 2023-04-14 | 2023-06-23 | 太和康美(北京)中医研究院有限公司 | Composition for inhibiting grease secretion and preparation method and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06321763A (en) | 1993-05-17 | 1994-11-22 | Kao Corp | Skin beautifying agent |
| EP1144997A3 (en) * | 1998-03-30 | 2002-08-28 | The Regents of the University of California | Methods and compounds for modulating nuclear receptor activity |
| KR100338654B1 (en) * | 2000-06-23 | 2002-05-30 | 임병철 | Ferulic ester derivative, 3,9-diferulylcoumestrol and cosmetic product containing the same |
| KR100628518B1 (en) | 2003-06-12 | 2006-09-26 | 김홍렬 | Extract of Glycine Semen Germinatum and functional cosmetics for the skin-aging protection containing the same |
| FR2863886B1 (en) * | 2003-12-22 | 2007-05-04 | Oreal | USE OF A STEREID OR NON-STEROIDAL LIGAND OF ECR RECEPTOR IN COSMETIC OR DERMATOLOGICAL PREPARATION TO MAINTAIN SKIN HOMEOSTASIS. |
| MXPA06013705A (en) * | 2004-05-28 | 2007-02-13 | Unigen Pharmaceuticals Inc | Diarylalkanes as potent inhibitors of binuclear enzymes. |
| KR20080018624A (en) * | 2006-08-25 | 2008-02-28 | 제노마인(주) | Use of an extract of organic selenium-enriched and sprouted bean |
| US9101161B2 (en) * | 2006-11-02 | 2015-08-11 | The Coca-Cola Company | High-potency sweetener composition with phytoestrogen and compositions sweetened therewith |
| KR100902326B1 (en) * | 2007-07-27 | 2009-06-12 | 주식회사 엘지생활건강 | Copmosition comprising extract of germinated soybean |
-
2011
- 2011-03-31 CN CN201510909598.0A patent/CN105362151A/en active Pending
- 2011-03-31 KR KR1020110029582A patent/KR20110110052A/en active Application Filing
- 2011-03-31 WO PCT/KR2011/002218 patent/WO2011122869A2/en active Application Filing
- 2011-03-31 CN CN2011800263374A patent/CN102905685A/en active Pending
- 2011-03-31 US US13/637,959 patent/US9265707B2/en active Active
- 2011-03-31 CN CN201410243191.4A patent/CN103989589B/en active Active
-
2014
- 2014-03-12 KR KR1020140028981A patent/KR20140040790A/en active Application Filing
-
2015
- 2015-08-20 KR KR1020150117315A patent/KR101677254B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20130071342A1 (en) | 2013-03-21 |
| CN102905685A (en) | 2013-01-30 |
| US9265707B2 (en) | 2016-02-23 |
| KR20110110052A (en) | 2011-10-06 |
| CN105362151A (en) | 2016-03-02 |
| KR20150101980A (en) | 2015-09-04 |
| CN103989589A (en) | 2014-08-20 |
| WO2011122869A2 (en) | 2011-10-06 |
| KR20140040790A (en) | 2014-04-03 |
| WO2011122869A3 (en) | 2012-02-02 |
| KR101677254B1 (en) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103989589B (en) | Beans extract containing coumestrol or comprising coumestrol, cosmetic composition for skin nursing | |
| ES2727832T3 (en) | Extract of aerial parts of Maca rich in polyphenols and composition comprising it | |
| US8771758B2 (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
| KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
| KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
| CN101146508A (en) | Cosmetic and cosmeceutical compositions for restoration of skin barrier function | |
| CN103260706B (en) | Composition comprising panlownin and/or Paulownia extract and application thereof | |
| JP5645344B2 (en) | External preparation composition | |
| TW201642849A (en) | Compositions including sesamin, methods of making and using the same in skin anti-aging and skin lightening applications | |
| KR20100124132A (en) | Anti-wrinkle cosmetic composition containing oriental herb extract treated by enzyme and its extraction method | |
| KR20100006796A (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
| JP2007126368A (en) | Antiaging agent, collagenase inhibitor and antioxidant | |
| BR102014025813A2 (en) | compositions comprising paulownia tomentosa wood extracts and uses thereof | |
| KR101969684B1 (en) | A cosmetic composition for anti-wrinkle and skin pore reduction containing natural spicule powder and natural complex extract | |
| KR100371504B1 (en) | Cosmetics composition comprising extract powder with vitis vinifera l.fermented solution and having whitening and anti-wrinkle effect | |
| KR20140081138A (en) | A skin-care agent containig Antrodia camphorata fruit body extract or Antrodia camphorata mycelium extract | |
| KR101402193B1 (en) | Cosmetic composition for skin whitening containig pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract or pleurotus ferulae mycelium culture fluid | |
| TW202102239A (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
| CN104470488B (en) | Expression modulation compositions of DICKKOPF 1 and application thereof | |
| KR20140012091A (en) | Composition comprising banyan tree, lotus, and clover serum fractions (hyperpigmentation) | |
| CN107427453A (en) | The peptide and glucosides extract of schisandra fruit and its improvement result to cutaneous nerve system response | |
| JP2012162487A (en) | Whitening agent, anti-aging agent and skin cosmetic | |
| KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
| KR20140081137A (en) | A skin-care agent containig Morchella esculenta fruit body extract or Morchella esculenta mycelium extract | |
| KR101458496B1 (en) | A skin-care agent for anti-inflammatory containig Pleurotus ferulae fruit body extract or Pleurotus ferulae mycelium extract or Pleurotus ferulae mycelium culture fluid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |